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LETTERS TO THE EDITOR
 
To the Editor—I have read with interest the article
by Weinstein et al. “Modeling for Health Care
and Other Policy Decisions: Uses, Roles, and Va-
lidity.” I agree with the authors that this is a con-
troversial area, but I am not sure that the authors
have considered what I would see as the funda-
mental questions in this debate: Who are the end-
users of “modeled” cost-effectiveness claims and
what are their information needs? Indeed, should
the focus of pharmacoeconomics be on making
recommendations as to the cost-effective use of
medical technologies, or should we be looking at
the wider picture?
When we consider the audiences for pharmaco-
economic techniques and analyses, they fall into
three groups:
 
1. pharmaceutical manufacturers in the drug-devel-
opment phase of any product who require
pharmacoeconomic analyses as inputs to busi-
ness-operations assessments and go/no-go deci-
sions in product development;
2. drug manufacturers and reimbursers who are
required to make submissions for formulary
listing and product positioning/evaluate reim-
bursement applications; and
3. drug manufacturers, health systems adminis-
trators, medical groups, and physicians/phar-
macists in the market-entry stage who are con-
cerned with making and evaluating marketing
claims for cost-effectiveness and considering
whether or not to actively follow up on a list-
ing of a drug (or a recommendation for use) by
encouraging patient switching.
Modeling, in its predictive sense, is critical to all
three audiences. But it is not just modeling to sup-
 
port cost-effectiveness claims. It is modeling to eval-
uate the anticipated impact of introducing a new
product on the health-care system: the impact on
the costs of health-care delivery and the impact on
the outcomes profile of the treating population. At
this level we have to be concerned with issues such
as consistency between targets of health care and
budgets allocated in that disease area, the extent
to which nonproductive treatment patterns can be
eliminated, and the effectiveness of alternative
care-management strategies. These issues are un-
likely to be addressed through decision-theoretic
models—the type of models that dominate the tra-
ditional pharmacoeconomics literature and which
are defended by Weinstein et al. against what they
see as unnecessary advocacy of empirical models.
A major criticism of the Weinstein paper there-
fore is that it fails to take account of the needs of
manufacturers and, ultimately, reimbursers (such
as NICE, Regence BlueShield) who are asking for
budget-impact assessments as well as the more tra-
ditional cost-effectiveness modeled claims. While
cost-effectiveness models (the synthetic mathemat-
ical simulations) may inform physicians in their
prescribing decisions and, indeed, medical direc-
tors in the advocacy of new products in formulary
committees, finance directors and those with re-
 
sponsibility for risk-managing populations are ask-
ing questions to which we have no answers.
From a drug manufacturer’s perspective, mod-
eled cost-effectiveness claims are only one aspect
of the range of information and assessments re-
quired in the decision to invest in a drug. The crit-
ical issues are unit pricing and patient switching.
In models of market potential, price is an indepen-
dent variable and manufacturers must be in-
formed, in as rigorous manner as possible, as to
the potential for the product at prices consistent
with capital budget conditions. Such assessments
have to occur at proof of concept and should be
revised continuously over the development pro-
cess. Modeling is important because it sets param-
 
eters not only for probability of success of cost-effec-
tiveness claims with reimbursers and prescribers,
but (and possibly more importantly) also for the
likely budget impact on health-care systems and
the risk of either being rejected on “affordability”
grounds or being restricted in use to a subpopula-
tion. This implies quite a different focus for mod-
 
eling, one that has to be integrated into the process
of business opportunity assessment and not one
that only attempts to extrapolate from clinical tri-
als in a simple decision driven framework.
What should we demand of a model? To an
economist, the emphasis that is given to nonpre-
dictive modeling seems odd. Indeed, to many
economists, particularly those who were exposed
early in their careers to Sir Karl Popper’s contribu-
tions to the philosophy of science, the claim that
economics has to being a social science rests on
the ability of practitioners to demonstrate that
they can improve our understanding and ability to
predict events in the real world—a process of 
 
con-
jecture
 
 and 
 
refutation.
 
 The emphasis, at least in
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economics (but perhaps pharmacoeconomics is
different?) is on the ability of a theory to provide a
successful explanation. While synthetic decision
models generate claims as to anticipated impacts,
that they are not meant to be subject to empirical
verification (or that they are in principle nonverifi-
able) seems to put them in the category of what
Popper would describe as pseudo-science. A claim
is a claim: until it is verified empirically it is noth-
ing more than a tautology (even if dressed up with
decision-theoretic rigor and subject to the criteria
advocated by Weinstein et al.).
From a health-system perspective, I would ar-
gue that empirical support for a drug impact claim
is critical. Claims that are not, in principle, ame-
nable to empirical verification should be rejected.
If I am managing a billion dollar health-care bud-
 
get, then I would like to be able to ask drug man-
ufacturers to stand behind their claims for cost-
effectiveness and budget impact and to provide
potentially quantifiable statements as to the im-
pact of a new drug in my treating population. Bas-
ing multimillion dollar decisions on nonverifiable
health-impact models is surely not acceptable.
Nor would a drug company be prepared to invest
millions of dollars in new drug development on
synthetic estimates of likely claims for cost-effec-
tiveness.
Should we wait for empirical verification of
cost-effectiveness claims before marketing or list-
ing a drug? I think the answer should be “yes”—
and put the onus on drug manufacturers to under-
take the necessary empirical studies. If such stud-
ies are not available, then the answer could be
provisional listing subject to post-entry evalua-
tions. If criteria for assessment are agreed, failure
to meet claimed targets could lead to price adjust-
ment, changing copayment level, restriction to a
subpopulation, or withdrawal from formulary sub-
sidization. Unfortunately, too few such validations
occur and health systems take synthetic cost-effec-
tiveness claims at face value.—Paul C. Langley
PhD, US and International Manager, Health Eco-
nomics, 3M Pharmaceuticals, St. Paul, MN
 
In reply
 
—We are grateful to Paul Langley and to
Reed Johnson and John Paul for raising important
concerns about the conduct and use of models in
 
health-care decision making. We concur with many
of their points, but take issue with others.
We agree with Dr. Langley that pharmacoeco-
nomic models can be directed to a wide range of
decision makers, including managed-care plans,
drug formularies, and pharmaceutical manufac-
turers themselves. We also agree that the quanti-
ties of primary interest to some decision makers
may be “bottom line” items such as budget im-
pact, market share, and the like. Our defense of
modeling to inform decisions about health-care re-
source allocation applies equally to these kinds of
business decisions: Models still serve as a vehicle
for synthesizing the information at hand in a
structured way that provides insights and may
even lead to better outcomes on average.
We also thank him for his observation that post
hoc validation of models against data can be a
valuable part of the modeling process. Both the
specification and parameter values of models can
and should be updated, or recalibrated, against
data as they emerge. Models that are susceptible
to such continuous evaluation are to be encour-
aged because they can focus the collection of em-
pirical evidence and reduce uncertainty in future
decisions. We disagree strongly, however, with
Dr. Langley’s statement that predictive validation
of models should be a prerequisite for their use as
inputs to decisions such as the listing of drugs.
The decision not to offer a drug to patients, or to
delay its availability, is itself a decision with health
and economic consequences. It is not automati-
cally true that to wait for conclusive evidence is
 
preferable to acting on the available evidence while
at the same time seeking additional evidence that
might cause reconsideration at a later time. In re-
ality it may be impossible to obtain true validation
of a decision, since that would require a compari-
son between two or more realities, of which only
one may be observable. It is also possible that un-
predicted events or misunderstood scientific con-
cepts may cause errors in a model’s predictions
under all choice alternatives without invalidating
the optimality of the chosen option over its alter-
natives. The decision-analytic concept of value of
information, which can be estimated only with the
use of models, provides the decision maker with the
ability to assess when the cost of obtaining, and
waiting for, confirmatory information is justified
by the expected benefit of avoiding errors by mak-
ing what may turn out to be an inferior decision.
We thank Dr. Johnson and Dr. Paul for point-
ing out the value of formal uncertainty assess-
ment. Monte Carlo sensitivity analysis is indeed
becoming more widely used, and it can offer deci-
sion makers a more precise characterization of
current information about the outcomes modeled.
The extension of this method into economic evalu-
ations is reflected in methods such as acceptability
 62
 
Letters to the Editor
 
curves and probability distributions of net health
benefits, and estimates of the expected value of in-
formation require one to specify probability distri-
butions for the parameters jointly and for the
structural assumptions. However, enhanced char-
acterization of uncertainty comes at a cost of in-
creased model complexity and loss of transpar-
ency. Moreover, the parameters and specifications
of the probability distributions on the parameter
values are themselves uncertain and may not re-
flect the beliefs of decision makers. Often a simple
N-way sensitivity analysis—taking care that the
parameters are specified so that their values are
reasonably judged to be probabilistically indepen-
dent—suffices to conclude that the qualitative re-
sult is robust. Lastly, we agree strongly with these
authors that the value of modeling efforts lies pri-
marily in their ability to provide insight into the
inherent trade-offs among competing alternatives,
to highlight important areas of future research,
and to provide one component of the decision-
making process, and not to deliver “nicely pack-
aged answers.”—Milton C. Weinstein, Karen M.
Kuntz, James K. Hammitt, Center for Risk Analy-
sis, Harvard School of Public Health, Boston, MA.
To the Editor—Weinstein et al.’s article and the
related editorial in 
 
Value in Health
 
 4:5 (Modeling
for Health Care and Other Policy Decisions: Uses,
Roles, and Validity) raise important questions
about the role of modeling in pharmacoeconom-
ics. The authors clearly elucidate concerns about
modeling in health-care applications from various
perspectives, although the relationship between
cost-effectiveness models and modeling applica-
tions in their example areas of environmental and
defense policy is not always apparent. Clearly, au-
diences for health-care models often suspect self-
interested motives on the part of modelers that
may be less of a factor in other policy areas. As a
remedy for such concerns, the authors advocate
greater transparency and improved scrutiny to
verify the validity of model results. Three years
ago the International Society for Pharmacoeco-
nomics and Outcomes Research (ISPOR) pub-
lished an advisory panel report that prescribed
similar verification procedures [1]. Although such
recommendations are helpful, the lack of informa-
tion that is inherent in modeling complex relation-
ships also sets inherent limits on our ability to ver-
ify model results.
Models are a way of organizing what we know.
They help explore complex interactions among
processes that may not be apparent to the unas-
sisted eye. However, anyone who has attempted to
construct a decision- or cost-effectiveness model
knows that most of the learning occurs during
model construction. Modeling requires analysts to
scrutinize the available evidence, weigh alternative
strategies for describing relationships among vari-
ables, and evaluate numerous judgments, often in
consultation with a variety of experts. Thus the
value of modeling is that it organizes both what
we know and what we don’t know about poten-
tial health-care intervention costs and outcomes. It
is specifically how our lack of knowledge is han-
dled in health-care modeling that can undermine
the credibility and usefulness of such models. Al-
though the process of modeling gives modelers a
reasonable idea of how well the model works, the
process of packaging, presenting, and interpreting
model results does not often convey those same in-
sights to potential users, leaving them suspicious
and at times antagonistic.
Accounting for uncertainty in health-care mod-
eling is often limited to simple sensitivity analysis.
Modelers alter one or more parameters, rerun the
model, and note the effect on results. There are
several problems with this approach. First, all the
parameters are more or less guesses, and the true
values almost certainly differ to some degree from
the constants used in the model. Users rarely re-
ceive much guidance from modelers on these ranges,
so it may not be easy to pick alternative values
that are empirically meaningful. Second, altering
one or two variables and showing that the results
do not change much ignores the potential for in-
teractions. If what is held constant were to change,
it is possible that marginal changes in these param-
eters could be much more significant. Thus, vary-
ing many parameters simultaneously could result
in quite different conclusions than varying individ-
ual parameters separately.
Conventions for doing sensitivity analysis high-
light the deficiency of most health-care models in
treating uncertainty fairly and transparently. Un-
like statistical models, cost-effectiveness models
rarely incorporate a clearly stated error structure.
However, there is no technological or method-
ological reason not to specify parameters as ran-
dom variables with clearly specified variances and
covariances. Variance arises from a number of
sources: measurement error, estimation error, er-
rors caused by adapting estimates from one con-
text to another, and errors related to such model-
ing judgments as selecting functional form or level
of aggregation [2]. There are many techniques for
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quantifying and managing these problems. For ex-
 
ample, there is extensive literature in environmental
economics on methods and limitations of transfer-
ring parameter estimates [3].
Once these variances and covariances are speci-
fied, Monte Carlo methods can then produce con-
fidence intervals to quantify the inherent uncer-
tainty in model predictions. Of course, if handled
honestly, the variance in assumed parameters for
some models may be so large that predictions could
range from minus to plus infinity. Far from being
a modeling failure, noisy results provide an oppor-
tunity to examine where our ignorance is greatest
and where the greatest payoff lies in investing in
better information. This kind of evaluation is pre-
sumably what Weinstein et al. have in mind when
they advocate “value-of-information” analysis.
Thus, we concur with the citation from George
Box in the article that “all models are wrong, but
some are useful.” Health-care modelers’ efforts will
become both more credible and more useful to de-
cision makers when they stop delivering nicely
packaged answers and start helping to define im-
portant questions.—F. Reed Johnson PhD, Princi-
pal Economist, and John E. Paul PhD, Division
Director, Health Economics and Quality of Life
RTI-Health Solutions, Research Triangle Park, NC.
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